| Autor: |
Jankie S; School of Pharmacy, University of the West Indies, St. Augustine Campus, Trinidad., Pinto Pereira LM; Department of Paraclinical Sciences, Faculty of Medical Sciences, University of the West Indies, St. Augustine Campus, Trinidad. |
| Jazyk: |
angličtina |
| Zdroj: |
Post reproductive health [Post Reprod Health] 2021 Mar; Vol. 27 (1), pp. 45-48. Date of Electronic Publication: 2020 Dec 25. |
| DOI: |
10.1177/2053369120982753 |
| Abstrakt: |
Menopause consequent to reduced circulating estrogen is associated with diminished insulin receptor sensitivity and fat redistribution, particularly central adiposity and increased waist circumference. Peri and menopausal women are at risk of hyperglycemia, prediabetes and attendant metabolic disturbances. Hormone replacement therapy increases insulin receptor sensitivity, but may precipitate an increased cardiovascular risk, depending on the route, if not commenced within the proposed period denoted by the 'timing hypothesis'. The therapeutic ideal of dietary modification with increased physical activity may have compliance issues. We theorize that selected antidiabetic agents reduce visceral fat deposits, restore insulin sensitivity and inhibit inflammatory mediator release. Glucagon-like peptide 1 agonists, sodium-glucose cotransporter 2 inhibitors and even metformin are worthy interventions to treat menopausal-induced obesogenic metabolic conditions. Loss of visceral fat restores insulin receptor sensitivity, decreases central obesity and adipokines to halt dysmetabolic changes. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
